PCSK9 and diabetes: is there a link?
Related Experiment Video
Updated: Mar 8, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Amir Abbas Momtazi1, Maciej Banach2, Matteo Pirro3
1Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.
Abstract:
Diabetes mellitus (DM) is associated with an increased risk of cardiovascular disease (CVD). Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as effective low-density lipoprotein cholesterol-lowering compounds. Although the results of available epidemiological, preclinical, and clinical studies suggest a positive association of plasma PCSK9 levels with glycemic parameters and risk of type 2 DM (T2DM), genetic findings have shown contradictory results. Overall, the impact of PCSK9 inhibitors on glycemic control parameters in patients with DM remains unclear. Here, we assess the available evidence for the association of PCSK9 status with the incidence and control of DM in preclinical and clinical studies, and identify molecular mechanisms regulating PCSK9 expression in the diabetic state.
Related Concept Videos
Coronary Artery Disease I: Introduction
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Pharmacogenomics: Identification of New Drug Targets
Peripheral Artery Disease I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Coronary Artery Disease II: Pathophysiology
